Morningstar brands and products Company Portfolio ...

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentations have concluded.

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, ...

Eupraxia's CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...

PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin ...

The full abstract will be available on the ASCO® website on May 22, 2025, at 5:00 p.m. ET.

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech ... today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic ...

Poster highlights potential predictive biomarker ... of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech ... today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic ...

CHICAGO, March 25, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung ...